These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

940 related items for PubMed ID: 26058549

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I, Kaspar B, Sharma U.
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Biosimilars: Practical Considerations for Pharmacists.
    Stevenson JG, Popovian R, Jacobs I, Hurst S, Shane LG.
    Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
    [Abstract] [Full Text] [Related]

  • 25. An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases.
    Wook Hong S, Kim YG, Ye BD.
    Immunotherapy; 2020 Jun; 12(9):609-623. PubMed ID: 32517574
    [Abstract] [Full Text] [Related]

  • 26. Biosimilars: are they bioequivalent?
    Gomollón F.
    Dig Dis; 2014 Jun; 32 Suppl 1():82-7. PubMed ID: 25531357
    [Abstract] [Full Text] [Related]

  • 27. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
    Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL.
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Biosimilars in ulcerative colitis: When and for who?
    Ilias A, Gonczi L, Kurti Z, Lakatos PL.
    Best Pract Res Clin Gastroenterol; 2018 Dec; 32-33():35-42. PubMed ID: 30060937
    [Abstract] [Full Text] [Related]

  • 30. Biosimilars in psoriasis: the future or not?
    Kellen R, Goldenberg G.
    Cutis; 2017 Feb; 99(2):116-120. PubMed ID: 28319617
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG.
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Biosimilar safety considerations in clinical practice.
    Choy E, Jacobs IA.
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [Abstract] [Full Text] [Related]

  • 36. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T, Letkovsky J.
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Biosimilars: From Extrapolation into Off Label Use.
    Zhao S, Nair JR, Moots RJ.
    Curr Pharm Des; 2017 Jun; 23(44):6746-6751. PubMed ID: 29189127
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.